Latest Immunosuppressive drug Stories
PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Soligenix, Inc.
Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs.
Three new reports describe biomarkers that identify either kidney transplant recipients likely to maintain excellent and stable allograft function in the absence of immunosuppressive drugs or those at risk of losing their transplants.
PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Soligenix, Inc.
PRINCETON, N.J., May 10 /PRNewswire-FirstCall/ -- Soligenix, Inc.
Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.
Kidney transplant recipients are known to have a higher risk of cancer, compared to the general population, due to the need to take immunosuppressive drugs to prevent organ rejection.
Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer.
ADDISON, Texas, April 21 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide.
Sirolimus-based immunosuppression and radiofrequency ablation are promising treatments for HCC.